In neuroendocrine tumors, mutation of the RET proto-oncogene was identified as the causative gene for human papillary and medullary thyroid carcinoma, as well as for neuroendocrine small cell lung cancers, and early clinical trials of Ret inhibitors show encouraging results [100,101,102,103]. This evidence concerns the gene RET and neuroendocrine neoplasm.